Latest Health stories from Life.
A recent KFF Health Tracking Poll indicates that MAHA voters are placing significant emphasis on reducing health care costs, overshadowing other health concerns.
A recent study raises questions about AI's effectiveness in diagnosis, alongside discussions on telehealth's impact on abortion access and an ongoing lawsuit involving Epic.
A new tracker compiles details on federal and state litigation related to abortion restrictions, including the FDA's approval of Mifepristone and other regulations.
A recent survey indicates that the pharmaceutical industry's reputation among patient groups has improved slightly over the past year. However, significant concerns regarding access to medications and pricing remain.
A leading Republican is raising concerns over whether the AMA's billing codes contribute to health care fraud, expanding the party's scrutiny of medical billing practices.
As analysts assess the implications of Lilly's liver case, questions arise about the thoroughness of their evaluations. This discussion highlights key biotech updates, including Cytokinetics' Myqorzo and Johnson & Johnson's IBD therapy.
In a recent announcement, HHS Secretary Robert F. Kennedy Jr. outlined plans to regulate the prescription of SSRIs, sparking discussions on mental health treatment.
Stay informed about hantavirus and other health topics, including the abortion pill and paternal deaths, as we provide the latest updates from Morning Rounds.
Cytokinetics' heart disease treatment Myqorzo, which has prior approval for one indication, has now successfully met efficacy targets in a Phase 3 trial for a genetic heart condition.
A recent analysis highlights the experiences of 52 health professionals who returned to 43 countries, revealing both challenges and opportunities that complicate the traditional narrative.
The recent hantavirus outbreak on a cruise ship serves as a stark reminder of the potential public health risks facing the U.S., especially following its withdrawal from the WHO.
An examination of artificial intelligence's potential and its constraints within the healthcare industry.
Johnson & Johnson is proceeding with its inflammatory bowel disease therapy, even though recent trials did not demonstrate a statistically significant benefit for patients.
France's medicines regulator has taken action against Novo Nordisk and Eli Lilly, imposing fines for their advertising practices related to weight loss.
The recent ruling by the 5th Circuit regarding mifepristone raises concerns not only for health care access but also for the future of drug innovation, as highlighted by Grace E. Colón.
In a significant ruling, the Supreme Court has reinstated broad access to the abortion pill mifepristone, countering a previous decision that could have disrupted abortion services nationwide.
The overall uninsured rate has risen in 2024 for the first time since 2019, affecting Hispanic, Black, and White individuals under 65 as Medicaid's continuous enrollment ends.
A recent research letter in JAMA Pediatrics highlights the need for more attention to paternal mortality, despite findings suggesting fatherhood may offer protective benefits.
A recent study on the implementation of AI in emergency rooms is drawing significant attention, but experts suggest that the excitement may be premature.
UCB is set to acquire a company specializing in antibody treatments for autoimmune diseases, highlighting ongoing shifts in the biotech landscape.